Markus K. Schuler

Dr. Markus K. Schuler

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MEMartin Eichler
Martin Eichler
LHLeopold Hentschel
Leopold Hentschel
SRStephan Richter
Stephan Richter
Peter HohenbergerPeter Hohenberger
Peter Hohenberger
Bernd KasperBernd Kasper
Bernd Kasper
TGthe PROSa Study Group
the PROSa Study Group
Sarcomas are rare cancers with high heterogeneity in terms of type, location, and treatment. The health-related quality of life (HRQoL) of sarcoma patients has rarely been investigated and is the subject of this analysis. Adult sarcoma patients and survivors were assessed between September 2017 and February 2019 in 39 study centers in Germany using standardized, validated questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)). Associated factors were analyzed exploratively using multivariable linear regressions. Among 1113 patients, clinically important limitations and symptoms were most pronounced in emotional (63%, 95% CI 60–66%), physical (60%, 95% CI 57–62%), role functioning (51%, 95% CI 48–54%), and pain (56%, 95% CI 53–59%) and fatigue (51%, 95% CI 48–54%). HRQoL differed between tumor locations with lower extremities performing the worst and sarcoma types with bone sarcoma types being most affected. Additionally, female gender, higher age, lower socioeconomic status, recurrent disease, not being in retirement, comorbidities, and being in treatment were associated with lower HRQoL. Sarcoma patients are severely restricted in their HRQoL, especially in functioning scales. The heterogeneity of sarcomas with regard to type and location is reflected in HRQoL outcomes. During treatment and follow-up, close attention has to be paid to the reintegration of the patients into daily life as well as to their physical abilities and emotional distress.

1 June 2015 in Cancer Epidemiology
Verified
Journal Article
Closed access
FTFreya Trautmann
Freya Trautmann
MSMarkus K. Schuler
Markus K. Schuler
JSJochen Schmitt
Jochen Schmitt

1 September 2015 in Clinical Imaging
Verified
Journal Article
Closed access
MSMarkus K. Schuler
Markus K. Schuler
IPIvan Platzek
Ivan Platzek
BBBettina Beuthien-Baumann
Bettina Beuthien-Baumann
MFMichael Fenchel
Michael Fenchel
GEGerhard Ehninger
Gerhard Ehninger
JHJörg van Den Hoff
Jörg van Den Hoff

1 March 2017 in Clinical Imaging
Verified
Journal Article
Closed access
IPIvan Platzek
Ivan Platzek
BBBettina Beuthien-Baumann
Bettina Beuthien-Baumann
GSGeorg Schramm
Georg Schramm
JMJens Maus
Jens Maus
MLMichael Laniado
Michael Laniado
MSMarkus K. Schuler
Markus K. Schuler

6 June 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KKKarin Kast
Karin Kast
MKMechthild Krause
Mechthild Krause
MSMarkus K. Schuler
Markus K. Schuler
KFKatrin Friedrich
Katrin Friedrich
BTBarbara Thamm
Barbara Thamm
SKStefan Krüger
Stefan Krüger
Li-Fraumeni-Syndrome (LFS) is an autosomal-dominant, inherited tumour predisposition syndrome associated with heterozygous germline mutations in the TP53 gene. Patients with LFS are at a high risk to develop early-onset breast cancer and multiple malignancies, among which sarcomas are the most common. A high incidence of childhood tumours and close to 100% penetrance has been described. Knowledge of the genetic status of the TP53 gene in these patients is critical not only due to the increased risk of malignancies, but also because of the therapeutic implications, since a higher rate of radiation-induced secondary tumours in these patients has been observed.

3 November 2015 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
MSMarkus K. Schuler
Markus K. Schuler
BHB. Hornemann
B. Hornemann
CPC. Pawandenat
C. Pawandenat
MKM. Kramer
M. Kramer
LHL. Hentschel
L. Hentschel
MBM. Bornhäuser
M. Bornhäuser